Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through strategic collaborations, milestone payments, and license fees. Its most advanced program is indiplon for insomnia, for which New Drug Applications (NDAs) were accepted by the FDA in 2005 with PDUFA action dates in early 2006.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 | Balance Sheet (Sep 30, 2005) |
|---|---|---|---|
| Total Revenues | $64,745 | $109,778 | - |
| Net Income (Loss) | $26,151 | $1,717 | - |
| Operating Expenses | $39,624 | $110,256 | - |
| Cash and Cash Equivalents | - | - | $75,384 |
| Short-term Investments | - | - | $215,454 |
| Total Current Assets | - | - | $297,628 |
| Total Debt (Current + Long-term) | - | - | $60,993 |
| Accumulated Deficit | - | - | $(276,238) |
Liquidity: As of September 30, 2005, the company held $290.8 million in cash, cash equivalents, and short-term investments. Management believes these resources are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Surge: Revenues for the three months ended September 30, 2005, increased to $64.7 million from $34.7 million in the same period in 2004. This 86% increase was driven primarily by a $50.0 million milestone payment from Pfizer related to the FDA acceptance of the NDA for indiplon tablets.
- Profitability Shift: The company reported a net income of $26.2 million for the quarter, compared to a net loss of $1.6 million in the prior year quarter. For the nine-month period, the company reported a net income of $1.7 million, a significant improvement from a net loss of $25.2 million in the prior year.
- Expense Trends:
- R&D Expenses: Decreased to $26.6 million (quarter) and remained flat at $81.9 million (nine months) compared to prior periods, due to the tapering of the indiplon development program.
- Sales, General & Administrative (SG&A): Increased significantly to $13.0 million (quarter) and $28.4 million (nine months) due to the build-out of a 200-person sales force to promote Pfizer's Zoloft and prepare for indiplon commercialization.
- Cash Flow: Net cash used in operating activities improved significantly to $7.9 million for the nine months ended September 30, 2005, compared to $70.9 million used in the prior year period.
Guidance, Outlook, and Risks
Outlook: Management expects to incur a net loss for the full year 2005 despite the strong third quarter, as R&D and commercialization expenses continue. Future profitability depends on FDA approval of indiplon and successful commercialization.
Key Catalysts:
- FDA action dates for indiplon capsule and tablet NDAs are set for February 15, 2006, and March 27, 2006, respectively.
- Revenue recognition is heavily dependent on milestone achievements and the timing of NDA filings.
Risks and Contingencies:
- Regulatory Risk: Failure to receive FDA approval for indiplon would severely harm the business. Even if approved, labeling restrictions could limit commercial success.
- Collaboration Dependence: The company relies heavily on Pfizer for funding, development, and commercialization of indiplon. Pfizer can terminate the collaboration with 180 days' notice.
- Accounting Changes: The company is preparing for the adoption of SFAS No. 123R (Share-Based Payment) in 2006, which will require expensing stock options and is expected to significantly impact reported results.
- Liquidity: While current resources are sufficient for 12 months, the company may require additional funding for future programs and may need to curtail operations if funding is unavailable.
Investor Verification Checklist
- Milestone Sustainability: Verify the timing and likelihood of future milestone payments from Pfizer, as current profitability is heavily skewed by one-time events.
- Indiplon Approval Status: Monitor FDA communications regarding the PDUFA dates (Feb/March 2006) and any potential delays or requests for additional data.
- Sales Force Costs: Assess the ongoing cost of the 200-person sales force and the revenue recognition schedule for the sales force allowance from Pfizer.
- Stock-Based Compensation Impact: Review the pro forma impact of SFAS 123R adoption on future earnings, as current reported income excludes significant stock option expenses.
- Debt Obligations: Confirm the terms and repayment schedule of the $61 million in total debt, including the current portion of $6.1 million.